Polyinosinic polycytidylic acid - PrEP Biopharm
Alternative Names: JNJ 43260295 AAM; Poly I: Poly C; Poly IC; Poly-ICLC - PrEP Biopharm; Polyinosinic-polycytidylic acid sodium salt; PrEP 001; Product Number WO 643Latest Information Update: 05 Nov 2021
Price :
$50 *
At a glance
- Originator Janssen Sciences Ireland UC
- Developer hVIVO; Janssen Research & Development; Janssen Sciences Ireland UC; PrEP Biopharm
- Class Adjuvants; Antineoplastics; Antivirals; Biopolymers; Oligonucleotides
- Mechanism of Action 2',5' oligoadenylate synthetase modulators; DDX58 protein modulators; IFIH1 protein modulators; Immunomodulators; Proto-oncogene protein c-rel modulators; Toll-like receptor 3 agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase II Influenza virus infections; Rhinovirus infections
- Preclinical COVID 2019 infections
Most Recent Events
- 28 Dec 2020 No recent reports of development identified for phase-I development in Rhinovirus-infections in USA (Intranasal, Spray)
- 16 Dec 2020 Preclinical trials in COVID-2019 infections (Prevention) in United Kingdom (Intranasal)
- 16 Dec 2020 PrEP Biopharm plans a phase IIb field trial for respiratory viruses including COVID-2019 infections, Influenza virus infections and Rhinovirus infections